Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

NCT03241810 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Stopped Merrimack Inc. terminated the trial early due to business decision

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Seribantumab
DRUG: Fulvestrant
DRUG: Placebo

Sponsor

Elevation Oncology